Psychopharmacology in HIV-infected patients

被引:20
作者
Repetto, Martin J. [1 ,2 ]
Petitto, John M. [3 ,4 ,5 ]
机构
[1] Univ Illinois, Dept Psychol, Champaign, IL 61820 USA
[2] Provena Covenant Med Ctr, Dept Psychiat, Champaign, IL 61820 USA
[3] Univ Florida, Coll Med, McKnight Brian Inst, Dept Psychiat, Gainesville, FL USA
[4] Univ Florida, Coll Med, McKnight Brian Inst, Dept Neurosci, Gainesville, FL USA
[5] Univ Florida, Coll Med, McKnight Brian Inst, Dept Pharmacol, Gainesville, FL USA
来源
PSYCHOSOMATIC MEDICINE | 2008年 / 70卷 / 05期
关键词
neuropsychiatric disorders; depression; highly active antiretroviral therapy; psychotropic medications;
D O I
10.1097/PSY.0b013e3181777190
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Neuropsychiatric disorders and syndromes may be underdiagnosed and inadequately treated in individuals infected with HIV. Depression in particular is among the most prevalent diagnoses, and data from controlled clinical studies have shown that antidepressant medications are efficacious and safe for treating depression in HIV-infected persons. A significant shortcoming of this literature is that most of the available data are from studies conducted before the advent of highly active antiretroviral therapy. In addition, apart from antidepressant medications, controlled studies systematically assessing efficacy and safety issues for other classes of psychotropic drugs (e.g., antipsychotic and anxiolytic medications) in HIV-infected persons are lacking. This review summarizes essential findings pertaining to the use of psychotropic medications to treat depression and other neuropsychiatric disorders in the context of HIV. It includes a discussion of clinically relevant treatment considerations (e.g., side effects, drug-drug interactions). derived from the existing literature as well as judgments that clinicians face in the absence of research data. Despite some shortcomings of the existing literature, overall there is compelling evidence that the appropriate use of psychotropic medications (coupled with behavioral therapy) can improve the quality of life of mentally ill HIV-infected individuals.
引用
收藏
页码:585 / 592
页数:8
相关论文
共 105 条
[1]  
*AG HLTH CAR POL R, HIV COST SERV UT STU
[2]   Could cholinesterase inhibitors and memantine alleviate HIV dementia? [J].
Alisky, JM .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 38 (01) :113-114
[3]   Valproic acid does not affect markers of human immunodeficiency virus disease progression [J].
Ances, Beau M. ;
Letendre, Scott ;
Buzzell, Maria ;
Marquie-Beck, Jennifer ;
Lazaretto, Deborah ;
Marcotte, Thomas D. ;
Grant, Igor ;
Ellis, Ronald J. .
JOURNAL OF NEUROVIROLOGY, 2006, 12 (05) :403-406
[4]   Memantine protects hippocampal neuronal function in murine human immunodeficiency virus type 1 encephalitis [J].
Anderson, ER ;
Gendelman, HE ;
Xiong, HG .
JOURNAL OF NEUROSCIENCE, 2004, 24 (32) :7194-7198
[5]   Hippocampal synaptic dysfunction in a murine model of human immunodeficiency virus type 1 encephalitis [J].
Anderson, ER ;
Boyle, J ;
Zink, WE ;
Persidsky, Y ;
Gendelman, HE ;
Xiong, H .
NEUROSCIENCE, 2003, 118 (02) :359-369
[6]  
[Anonymous], 2000, Am J Psychiatry, V157, P1
[7]   What is a "mood stabilizer"? An evidence-based response [J].
Bauer, MS ;
Mitchner, L .
AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (01) :3-18
[8]  
Bellibas SE, 1999, ANTIMICROB AGENTS CH, V43, P1815, DOI 10.1128/AAC.43.7.1815
[9]   HIV dementia and the basal ganglia [J].
Berger, JR ;
Nath, A .
INTERVIROLOGY, 1997, 40 (2-3) :122-131
[10]   Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States [J].
Bing, EG ;
Burnam, A ;
Longshore, D ;
Fleishman, JA ;
Sherbourne, CD ;
London, AS ;
Turner, BJ ;
Eggan, F ;
Beckman, R ;
Vitiello, B ;
Morton, SC ;
Orlando, M ;
Bozzette, SA ;
Ortiz-Barron, L ;
Shapiro, M .
ARCHIVES OF GENERAL PSYCHIATRY, 2001, 58 (08) :721-728